Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

October 30, 2023

Study Completion Date

April 30, 2024

Conditions
Ischemic StrokeAlteplase Adverse Reaction
Interventions
DRUG

Alteplase

Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.

DRUG

Alteplase

Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.

Trial Locations (1)

33155

Kafr Elsheikh University Hospital, Kafr ash Shaykh

All Listed Sponsors
lead

Kafrelsheikh University

OTHER